All News

ra.hands2_.JPG

Comorbidities Increase in Importance in RA

d RheumNow

Patients with rheumatoid arthritis (RA) have a large comorbidity burden at the time of diagnosis, including a wide range of ailments but with pulmonary disease a particular concern, a U.K. population-based study found.

Read Article
RN.podcast.resized.jpg

RheumNow Podcast – Fight or Switching (DMARDs) (10.18.19)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article
joint.injx_.jpg

Joint Injections: Are They Worth the Risk?

d RheumNow

Intra-articular injections of corticosteroids for relief of the pain of hip or knee osteoarthritis (OA) may have adverse long-term consequences, researchers suggested.

Read Article
heart-attack.jpg

Protective Effects of ASA and Vasodilators in Systemic Sclerosis

d Jack Cush, MD

A large cohort study suggests that the use of vasodilators and aspirin (ASA) in systemic sclerosis (SSc) may yield favorable  cardiovascular outcomes.

Read Article
OP_0.jpg

High Dose Statins Increase Odds of Osteoporosis

d Jack Cush, MD

It is unknown if inhibiting cholesterol synthesis (with statins) might influence sex-hormone production and therefore, the risk of osteoporosis. A new study shows that, in statin-treated individuals, the development of osteoporosis is statin dose-dependent.

Read Article
Retrospective study of 102 RA patients interstitial lung dz, and 52% had progressive fibrosing-ILD; these were associated with increased mortality. Predictors of mortality were DLco and high titres https://t.co/Ydd9xAhsag IgM rheumatoid factor

Links:

Dr. John Cush RheumNow ( View Tweet)

The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) has recommended marketing authorization for upadacitinib (Rinvoq) for the treatment of rheumatoid arthritis #RA. https://t.co/xnun9oiO9q

Links:

Dr. John Cush RheumNow ( View Tweet)

THe European Medicines Agency committee announced a positive opinion recommending romosozumab for the treatment of severe osteoporosis in postmenopausal women at high Fracture risk for fracture w/ no hx of MI/CVA https://t.co/sr7iPaSngj

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast is up! The week in review - Watch it here>> https://t.co/c0EPyvKNWD or listen to the podcast in your car (Android Auto, Apple Car play) or here>> https://t.co/xZWQTszGn9

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast is up! The week in review - on statins, Comorbidities, ANA specificity, APL Ab effects, PsA surgery & more. Watch it here>> https://t.co/c0EPyvKNWD or listen to the podcast in your car (Android Auto, Apple Car play) or here>> https://t.co/xZWQTszGn9

Links:

Dr. John Cush RheumNow ( View Tweet)

Risk of uveitis in JIA - study 2294 JIA pts in the UK JIA registries finds that uveitis occured in 27/943 MTX, 16/1047, and only 1 of 304 adalimumab/infliximab Rx pts. No difference w/ MTX & etanercept, but much less with adalimumab https://t.co/rO13LznMmm

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow survey for Rheumatologists – When treating GCA, when do you add a steroid sparing agent? https://t.co/qhpOxYhsYV

Links:

Dr. John Cush RheumNow ( View Tweet)

Study of RA complications from National Inpatient Sample data (2005-14) show #RA higher risk for MI (OR 1.03), COPD (1.67), CVA ( 2.2), renal Dz (1.42), EtOH abuse (2.73). Mortality trend increased significantly for CHF (P = 0.025) & AFib (P = 0.042) https://t.co/NzKPWsyKgA

Links:

Dr. John Cush RheumNow ( View Tweet)

RHEUMATOLOGISTS - In what percentage of your GCA patients do you use a steroid-sparing agent? Few, Some, Many? RHEUMNOW Live Vote: Rheums Click here>> https://t.co/qhpOxYhsYV

Links:

Dr. John Cush RheumNow ( View Tweet)

NEJM Case: 4-year-old girl with juvenile dermatomyositis refractory to multiple therapies has active rash, weakness & extensive calcification and strongly positive for anti–NXP-2 . Improved w/ infliximab, thalidomide, aluminum hydroxide. https://t.co/Wbb6JEMtrh

Links:

Dr. John Cush RheumNow ( View Tweet)

Survey for RHEUMATOLOGISTS - When choosing drug therapy for GCA, what mechanism are you targeting? IL-1, IL-6, TNF, or inflammation in general? Please vote at RheumNow >> https://t.co/qhpOxYhsYV

Links:

Dr. John Cush RheumNow ( View Tweet)

LIVE VOTE Survey: When treating a patient for GCA, when might you add a steroid-sparing agent?? If youre a RHEUMATOLOGIST - please vote in our RheumNow quick 4Q survey https://t.co/qhpOxYhsYV

Links:

Dr. John Cush RheumNow ( View Tweet)

The risks of pulmonary embolism after 6 types of surgery assessed using 60703 patients in a French national database. PE risk elevated for 12 weeks, highest in 6wks Pos-Op.

Dr. John Cush RheumNow ( View Tweet)

UK population study of 6591incident RA patients shows comorbidity increased all-cause mortality (aHR 1.26; 1-1.6). Joint destruction had no effect, but COPD was associated with significantly more mortality (COPD HR 2.84; 1.13-7.12). https://t.co/6ULPvq34qh

Links:

Dr. John Cush RheumNow ( View Tweet)

RHEUMATOLOGIST SURVEY - In what percentage of your GCA patients do you use a steroid-sparing agent? Few, Some, Many? RHEUMNOW Live Vote: Rheums Click here>> https://t.co/qhpOxYhsYV

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×